Abstract:ABSTRACT The success of future clinical trials with oncolytic viruses depends on the identification and the control of mechanisms that modulate their therapeutic efficacy. In particular, little is known about the role of autophagy in infection by attenuated measles virus of the Edmonston strain (MV-Edm). We investigated the interaction between autophagy, innate immune response, and oncolytic activity of MV-Edm, since the antiviral immune response is a known factor limiting virotherapies. We report that MV-Edm exploits selective autophagy to mitigate the innate immune response mediated by DDX58/RIG-I like receptors (RLRs) in non-small cell lung cancer (NSCLC) cells. Both RNA interference (RNAi) and overexpression approaches demonstrate that autophagy enhances viral replication and inhibits the production of type I interferons regulated by RLRs. We show that MV-Edm unexpectedly triggers SQSTM1/p62-mediated mitophagy, resulting in decreased mitochondrion-tethered mitochondrial antiviral signaling protein (MAVS) and subsequently weakening the innate immune response. These results unveil a novel infectious strategy based on the usurpation of mitophagy leading to mitigation of the innate immune response. This finding provides a rationale to modulate autophagy in oncolytic virotherapy. IMPORTANCE In vitro studies, preclinical experiments in vivo , and clinical trials with humans all indicate that oncolytic viruses hold promise for cancer therapy. Measles virus of the Edmonston strain (MV-Edm), which is an attenuated virus derived from the common wild-type measles virus, is paradigmatic for therapeutic oncolytic viruses. MV-Edm replicates preferentially in and kills cancer cells. The efficiency of MV-Edm is limited by the immune response of the host against viruses. In our study, we revealed that MV-Edm usurps a homeostatic mechanism of intracellular degradation of mitochondria, coined mitophagy, to attenuate the innate immune response in cancer cells. This strategy might provide a replicative advantage for the virus against the development of antiviral immune responses by the host. These findings are important since they may not only indicate that inducers of autophagy could enhance the efficacy of oncolytic therapies but also provide clues for antiviral therapy by targeting SQSTM1/p62-mediated mitophagy.

[Advances in Measles Virus for Cancer Therapy].

Measles to the Rescue: A Review of Oncolytic Measles Virus

Measles Virus as an Oncolytic Immunotherapy

Measles Virus for Cancer Therapy

Recombinant Chinese Hu191 Measles Virus Exhibits a Significant Antitumor Activity Against Nephroblastoma Mediated by Immunogenic Form of Apoptosis.

Engineered Measles Virus Edmonston Strain Used As a Novel Oncolytic Viral System Against Human Neuroblastoma Through a CD46 and Nectin 4-Independent Pathway

Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model

Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics

A vector-encoded bispecific killer engager to harness virus-activated NK cells as anti-tumor effectors

Oncolytic vaccinia virus and cancer immunotherapy

[Oncolytic Paramyxoviruses: Mechanism of Action, Preclinical and Clinical Studies]

[The Advances of Oncolytic Herpes Simplex Virus in Cancer Therapy].

Mitophagy Enhances Oncolytic Measles Virus Replication by Mitigating Ddx58/Rig-I-Like Receptor Signaling

In Vitro Sensitivity of Neuroendocrine Neoplasms to an Armed Oncolytic Measles Vaccine Virus

Forskolin Enhances Antitumor Effect of Oncolytic Measles Virus by Promoting Rab27a Dependent Vesicular Transport System

Oncolytic Measles Virus Enhances Antitumour Responses of Adoptive CD8+NKG2D+ Cells in Hepatocellular Carcinoma Treatment

MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer

Carrier Cells for Delivery of Oncolytic Measles Virus into Tumors: Determinants of Efficient Loading

A novel approach for breast cancer treatment: the multifaceted antitumor effects of rMeV-Hu191

Chemokine Expression from Oncolytic Vaccinia Virus Enhances Vaccine Therapies of Cancer

Oncolytic vaccinia virus: from bedside to benchtop and back